Follicular Lymphoma  >>  oxaliplatin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
NCT02624492 / 2014-004794-16: To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL

Completed
2
21
Europe
BI 836826, GemOx, Rituximab
Boehringer Ingelheim
Lymphoma, Large B-Cell, Diffuse
03/18
03/18
2019-002373-59: A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma. Eine Phase-II-Studie zur Untersuchung von Gemcitabin/Oxaliplatin/Rituximab mit Tafasitamab (MOR-00208) bei Patienten mit aggressivem Lymphom.

Ongoing
2
64
Europe
Tafasitamab, MOR00208, Lyophilisate for solution for infusion, MINJUVI® 200 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
University Medical Center of the Johannes Gutenberg University Mainz, Incyte Corporation
Malignant B-cell lymphoma Aggressives B-Zell Lymphom, Malignant Lymphoma Aggressives Lymphom, Diseases [C] - Cancer [C04]
 
 
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/27
ZUMA-1, NCT02348216 / 2015-005007-86: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Checkmark Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Feb 2021 - Feb 2021: Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASH 2020
More
Completed
1/2
307
Europe, Canada, US, RoW
Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Kite, A Gilead Company
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
07/23
07/23
NCT02953509 / 2016-003408-29: Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Checkmark Data from P1b trial in combination with rituximab for DLBCL at ASH 2022
Jan 2023 - Jan 2023: Data from P1b trial in combination with rituximab for DLBCL at ASH 2022
Hourglass Apr 2020 - Sep 2020 : Safety and efficacy data from P1b trial in combination with rituximab for DLBCL
Checkmark In combination with rituximab in DLBCL and FL patents at EHA 2019 [screenshot]
Jun 2019 - Jun 2019: In combination with rituximab in DLBCL and FL patents at EHA 2019 [screenshot]
More
Terminated
1/2
178
Europe, US, RoW
Magrolimab, Hu5F9-G4, Rituximab, RITUXAN®, MabThera, Gemcitabine, Gemzar®, Oxaliplatin, Eloxatin®
Gilead Sciences, The Leukemia and Lymphoma Society
Non Hodgkin Lymphoma
03/24
03/24
EPCORE NHL-3, NCT04542824: Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL

Active, not recruiting
1/2
102
Japan
epcoritamab (monotherapy), GEN3013, DuoBody®-CD3xCD20, EPKINLY™, epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP, gemcitabine and oxaliplatin, Gemox, epcoritamab (maintenance), rituximab and lenalidomide, R2
Genmab, AbbVie
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
12/24
12/24
EPCORE NHL-2, NCT04663347 / 2020-000845-15: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Checkmark Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Checkmark Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Checkmark Data from arm-4 of EPCORE NHL-2 trial for r/r DLBCL at ASH 2022
More
Recruiting
1/2
662
Europe, US, RoW
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP, rituximab and lenalidomide, R2, rituximab and bendamustine, BR, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, R-DHAX/C, gemcitabine and oxaliplatin, GemOx, Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, R mini-CHOP, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate, R-ICE
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
03/29
03/29

Download Options